pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

Anthropic AI reports first scientific discovery: new enzyme system

Oct 1, 2026·read at Endpoints ↗Positive

Anthropic announced that its Claude AI system has identified a previously unknown enzyme system, marking the company's first reported scientific discovery.

The life sciences team, led by Eric Kauderer‑Abrams, discussed the finding in a Q&A, describing how the AI agents generated the insight and outlining the potential implications for biotechnology research.

Anthropic said the discovery will feed into its biology lab efforts and a pre‑clinical pipeline, though details on downstream development remain limited.

The company highlighted the role of AI in accelerating early‑stage research, positioning the breakthrough as a proof‑of‑concept for future applications in drug discovery.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Q&A: Anthropic's life sciences team talk Claude's first scientific discovery”

read at Endpoints ↗
94 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Zymeworks Inc.2

related stories

  • Aug 7BioMarin discontinues rare disease drug; CSL and Arcturus split upEndpoints
  • Aug 6Intellia identifies genetic risk factor for liver complications in CRISPR trialEndpoints
  • Jul 1FDA warns Genzyme's Irish site over quality questionsEndpoints
  • Jun 30Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe diseaseEndpoints
  • May 19BioMarin's rare disease therapy shows no clinical benefit in Phase 3 testEndpoints